

Juan G Abrales

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4498746/publications.pdf>

Version: 2024-02-01

170
papers

16,989
citations

15504

65
h-index

15266

126
g-index

178
all docs

178
docs citations

178
times ranked

10326
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding Preferences Toward Virtual Care: A Pre-COVID Mixed Methods Study Exploring the Perspectives of Patients with Chronic Liver Disease. <i>Telemedicine Journal and E-Health</i> , 2022, 28, 407-414.	2.8	6
2	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1636-1662.e36.	4.4	95
3	Use of the Molecular Adsorbent Recirculating System in Acute Liver Failure: Results of a Multicenter Propensity Score-Matched Study*. <i>Critical Care Medicine</i> , 2022, 50, 286-295.	0.9	19
4	Frailty is associated with increased risk of cirrhosis disease progression and death. <i>Hepatology</i> , 2022, 75, 600-609.	7.3	36
5	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e289-e297.	4.4	17
6	Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, Canada. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1170-e1179.	4.4	32
7	Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000798.	2.7	3
8	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. <i>Gut</i> , 2022, 71, 1856-1866.	12.1	17
9	Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list. <i>Hepatology Communications</i> , 2022, 6, 1699-1710.	4.3	8
10	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-ACH). <i>Liver International</i> , 2022, 42, 1109-1120.	3.9	20
11	Association between gut colonization of vancomycin-resistant enterococci and liver transplant outcomes. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	6
12	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	4.3	5
13	Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation. <i>Clinical Infectious Diseases</i> , 2021, 72, 845-852.	5.8	8
14	Nonalcoholic Fatty Liver Disease: A Special Consideration in Transjugular Intrahepatic Portosystemic Shunts?. <i>Liver Transplantation</i> , 2021, 27, 323-324.	2.4	1
15	Royal Free Hospital-estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. <i>Liver International</i> , 2021, 41, 819-827.	3.9	2
16	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	3.7	16
17	Impact of specialized multidisciplinary care on cirrhosis outcomes and acute care utilization. <i>Canadian Liver Journal</i> , 2021, 4, 38-50.	0.9	5
18	A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. <i>BMC Gastroenterology</i> , 2021, 21, 120.	2.0	18

#	ARTICLE	IF	CITATIONS
19	The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis. <i>Clinics in Liver Disease</i> , 2021, 25, 327-343.	2.1	16
20	Assessing Patient Proficiency with Internet-Connected Technology and Their Preferences for E-Health in Cirrhosis. <i>Journal of Medical Systems</i> , 2021, 45, 72.	3.6	5
21	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021, 75, 1026-1033.	3.7	59
22	Using Patient Completed Screening Tools to Predict Risk of Malnutrition in Patients With Inflammatory Bowel Disease. <i>Crohn's & Colitis</i> 360, 2021, 3, .	1.1	11
23	Statins and Liver Cancer in Cirrhosis: The Most Relevant Questions Are Still Unanswered. <i>American Journal of Gastroenterology</i> , 2021, 116, 2197-2198.	0.4	1
24	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. <i>Liver Transplantation</i> , 2021, 27, 1382-1391.	2.4	4
25	The 6-Minute Walk Test Distance Predicts Mortality in Cirrhosis: A Cohort of 694 Patients Awaiting Liver Transplantation. <i>Liver Transplantation</i> , 2021, 27, 1490-1492.	2.4	8
26	The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. <i>Journal of Hepatology</i> , 2021, 75, S118-S134.	3.7	30
27	Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials. <i>Hepatology</i> , 2021, 74, 3301-3315.	7.3	19
28	Non-invasive alloimmune risk stratification of long-term liver transplant recipients. <i>Journal of Hepatology</i> , 2021, 75, 1409-1419.	3.7	31
29	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28
30	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 589-599.	3.7	36
31	Liver cirrhosis. <i>Lancet</i> , The, 2021, 398, 1359-1376.	13.7	515
32	Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?. <i>Journal of Hepatology</i> , 2021, 75, 750-752.	3.7	2
33	Nonselective Beta-Blockers in Compensated Cirrhosis: Preventing Variceal Hemorrhage or Preventing Decompensation?. <i>Gastroenterology</i> , 2021, 161, 770-773.	1.3	20
34	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100368.	4.9	3
35	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100364.	4.9	9
36	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 71, 522-538.	7.3	151

#	ARTICLE	IF	CITATIONS
37	The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. <i>Journal of Hepatology</i> , 2020, 72, 391-400.	3.7	119
38	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
39	Advanced Practice Providers: Raising Our Defenses Against the Rising Tide of Cirrhosis. <i>Hepatology</i> , 2020, 71, 11-13.	7.3	0
40	Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. <i>Hepatology</i> , 2020, 72, 1029-1042.	7.3	14
41	Can We Add the History of the Nonoperative Therapy of Varices to Other Success Chapters of Modern Medicine?. <i>Clinical Liver Disease</i> , 2020, 16, 73-82.	2.1	2
42	Practical management of esophageal varices in the context of SARS-CoV-2 (COVID-19): the Alberta protocol. <i>Canadian Liver Journal</i> , 2020, 3, 300-303.	0.9	6
43	Reply. <i>Hepatology</i> , 2020, 72, 2239-2240.	7.3	0
44	The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial. <i>BMC Health Services Research</i> , 2020, 20, 558.	2.2	14
45	Cirrhosis as new indication for statins. <i>Gut</i> , 2020, 69, 953-962.	12.1	81
46	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 159, 1839-1852.	1.3	103
47	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	7.3	74
48	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. <i>Hepatology</i> , 2020, 72, 1353-1365.	7.3	32
49	Classifying varices in cirrhosis: Who's got the best look?. <i>Liver International</i> , 2020, 40, 754-755.	3.9	1
50	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
51	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	7.3	144
52	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. <i>Journal of Hepatology</i> , 2019, 71, 942-950.	3.7	61
53	Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2320-2329.e12.	4.4	87
54	Simple Clinical Tools to Predict Decompensation in Patients With Compensated Cirrhosis: An Unmet Need. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2179-2181.	4.4	13

#	ARTICLE	IF	CITATIONS
55	Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). <i>Annals of Hepatology</i> , 2019, 18, 518-535.	1.5	69
56	Editorial: is there a causal link between non-selective beta blockers and portal vein thrombosis in cirrhosis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 819-820.	3.7	1
57	Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure. <i>Liver International</i> , 2019, 39, 1271-1280.	3.9	31
58	β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet</i> , 2019, 393, 1597-1608.	13.7	375
59	Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. <i>Liver International</i> , 2019, 39, 1437-1447.	3.9	91
60	The direct and indirect effects of vancomycin-resistant enterococci colonization in liver transplant candidates and recipients. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 363-373.	4.4	7
61	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019, 575, 505-511.	27.8	493
62	Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 20-30.	3.7	68
63	Child-Pugh Classification: Time to Abandon?. <i>Seminars in Liver Disease</i> , 2019, 39, 096-103.	3.6	49
64	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <i>Hepatology</i> , 2019, 69, 1287-1299.	7.3	45
65	Colder Weather and Fewer Sunlight Hours Increase Alcohol Consumption and Alcoholic Cirrhosis Worldwide. <i>Hepatology</i> , 2019, 69, 1916-1930.	7.3	34
66	Depression in cirrhosis – a prospective evaluation of the prevalence, predictors and development of a screening nomogram. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 194-201.	3.7	40
67	The impact of delayed source control and antimicrobial therapy in 196 patients with cholecystitis-associated septic shock: a cohort analysis. <i>Canadian Journal of Surgery</i> , 2019, 62, 189-198.	1.2	6
68	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 396-405.	3.7	144
69	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
70	Home Exercise Training Improves Exercise Capacity in Cirrhosis Patients: Role of Exercise Adherence. <i>Scientific Reports</i> , 2018, 8, 99.	3.3	89
71	Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. <i>Journal of Hepatology</i> , 2018, 69, 626-634.	3.7	46
72	The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 226-240.	0.8	29

#	ARTICLE	IF	CITATIONS
73	Multicenter External Validation of Risk Stratification Criteria for Patients With Variceal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 132-139.e8.	4.4	54
74	The impact of obesity in cirrhotic patients with septic shock: A retrospective cohort study. <i>Liver International</i> , 2018, 38, 1230-1241.	3.9	11
75	Acute Variceal Bleeding: Does Octreotide Improve Outcomes in Patients with Different Functional Hepatic Reserve?. <i>Annals of Hepatology</i> , 2018, 17, 125-133.	1.5	1
76	An update on the management of acute esophageal variceal bleeding. <i>GastroenterologÃa Y HepatologÃa</i> , 2017, 40, 34-40.	0.5	16
77	Reply. <i>Hepatology</i> , 2017, 65, 2131-2132.	7.3	0
78	The Design of Clinical Trials in Portal Hypertension. <i>Seminars in Liver Disease</i> , 2017, 37, 073-084.	3.6	11
79	An update on the management of acute esophageal variceal bleeding. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2017, 40, 34-40.	0.1	0
80	Beta-blockers in patients with advanced liver disease: Has the dust settled?. <i>Liver Transplantation</i> , 2017, 23, 1058-1069.	2.4	24
81	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. <i>Hepatology</i> , 2017, 66, 1219-1231.	7.3	80
82	Reply to: "Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: Methodological issues of confounding and prediction models". <i>Journal of Hepatology</i> , 2017, 66, 865.	3.7	1
83	Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. <i>Hepatology</i> , 2017, 66, 1980-1988.	7.3	223
84	Reply. <i>Liver Transplantation</i> , 2017, 23, 1353-1353.	2.4	1
85	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. <i>Hepatology</i> , 2017, 65, 310-335.	7.3	1,520
86	Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction. <i>World Journal of Gastroenterology</i> , 2017, 23, 6777-6787.	3.3	30
87	Patient-perceived barriers to lifestyle interventions in cirrhosis. <i>Saudi Journal of Gastroenterology</i> , 2017, 23, 97.	1.1	29
88	Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. <i>Journal of Hepatology</i> , 2016, 65, 998-1005.	3.7	84
89	A Model to Identify Sarcopenia in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1473-1480.e3.	4.4	175
90	Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts. <i>Liver Transplantation</i> , 2016, 22, 1333-1342.	2.4	36

#	ARTICLE	IF	CITATIONS
91	Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. <i>Hepatology</i> , 2016, 64, 2173-2184.	7.3	251
92	STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?. <i>Hepatology</i> , 2016, 64, 13-15.	7.3	9
93	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	1.3	232
94	Clinical Trial Watch: Reports from the Liver Meeting® [®] , AASLD, San Francisco, November 2015. <i>Journal of Hepatology</i> , 2016, 64, 1428-1445.	3.7	3
95	Statins: the Panacea of Cirrhosis?. <i>Current Hepatology Reports</i> , 2016, 15, 1-7.	0.9	8
96	Relevance of New Definitions to Incidence and Prognosis of Acute Kidney Injury in Hospitalized Patients with Cirrhosis: A Retrospective Population-Based Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0160394.	2.5	57
97	Prognosis of acute variceal bleeding: Is being on beta-blockers an aggravating factor? A short-term survival analysis. <i>Hepatology</i> , 2015, 62, 1840-1846.	7.3	11
98	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015, 62, 762-772.	7.3	230
99	The Use of Beta-Blockers in Advanced Cirrhosis "Where Do We Stand?. <i>Current Hepatology Reports</i> , 2015, 14, 46-52.	0.9	1
100	Clinical trial watch: Reports from the AASLD Liver Meeting® [®] , Boston, November 2014. <i>Journal of Hepatology</i> , 2015, 62, 1196-1203.	3.7	22
101	Soft and hard endpoints in acute variceal bleeding. <i>Hepatology</i> , 2015, 61, 762-765.	7.3	7
102	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 985-992.	0.4	25
103	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. <i>Journal of Hepatology</i> , 2015, 63, 753-762.	3.7	5
104	Insufficient Protein Intake Is Associated With Increased Mortality in 630 Patients With Cirrhosis Awaiting Liver Transplantation. <i>Nutrition in Clinical Practice</i> , 2015, 30, 530-536.	2.4	71
105	Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt - When and How?. <i>Digestive Diseases</i> , 2015, 33, 524-533.	1.9	8
106	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Gut</i> , 2015, 64, 1434-1443.	12.1	159
107	Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, 1068-1075.	3.7	183
108	Risk of Bacterial Infection in Patients With Cirrhosis and Acute Variceal Hemorrhage, Based on Child "Pugh Class, and Effects of Antibiotics. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1189-1196.e2.	4.4	83

#	ARTICLE	IF	CITATIONS
109	Assessment and Management of Portal Hypertension. , 2015, , 3667-3686.		0
110	Comorbidities have a limited impact on post-transplant survival in carefully selected cirrhotic patients: a population-based cohort study. <i>Annals of Hepatology</i> , 2015, 14, 505-14.	1.5	1
111	Assessment and Management of Portal Hypertension. , 2014, , 1-25.		0
112	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. <i>Gastroenterology</i> , 2014, 146, 412-419.e3.	1.3	285
113	Liver sinusoidal endothelial dysfunction after LPS administration: A role for inducible-nitric oxide synthase. <i>Journal of Hepatology</i> , 2014, 61, 1321-1327.	3.7	58
114	Measurement of Portal Pressure. <i>Clinics in Liver Disease</i> , 2014, 18, 779-792.	2.1	55
115	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	1.3	353
116	Eight Weeks of Exercise Training Increases Aerobic Capacity and Muscle Mass and Reduces Fatigue in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1920-1926.e2.	4.4	180
117	Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. <i>Journal of Hepatology</i> , 2013, 58, 45-50.	3.7	259
118	Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 102-111.e1.	1.3	437
119	Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. <i>Hepatology</i> , 2013, 57, 1172-1181.	7.3	84
120	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study. <i>Liver Transplantation</i> , 2013, 19, 450-456.	2.4	8
121	Spleen stiffness: Toward a noninvasive portal sphygmomanometer?. <i>Hepatology</i> , 2013, 57, 1278-1280.	7.3	22
122	Insulin resistance in patients with cirrhosis and portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1458-G1465.	3.4	23
123	Acute Variceal Bleeding. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 46-54.	2.1	62
124	Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 584-590.	4.7	50
125	Hypercoagulability in Patients With Chronic Noncirrhotic Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 72-78.	4.4	36
126	Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 776-783.	4.4	407

#	ARTICLE	IF	CITATIONS
127	Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. <i>Gastroenterology</i> & <i>Hepatology</i> , 2012, 35, 488-495.	0.5	37
128	Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD. <i>PLoS ONE</i> , 2012, 7, e32785.	2.5	180
129	Insulin resistance and liver microcirculation in a rat model of early NAFLD. <i>Journal of Hepatology</i> , 2011, 55, 1095-1102.	3.7	64
130	Portal cholangiopathy: radiological classification and natural history. <i>Gut</i> , 2011, 60, 853-860.	12.1	88
131	The Treatment and Prevention of Variceal Bleeding. , 2011, , 477-500.		0
132	Portal Hypertension: Extrahepatic Mechanisms. , 2011, , 91-100.		0
133	An uncommon cause of massive scrotal enlargement. <i>Liver International</i> , 2010, 30, 995-995.	3.9	0
134	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. <i>Hepatology</i> , 2010, 52, 1783-1790.	7.3	88
135	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2010, 52, 2044-2052.	7.3	180
136	Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. <i>New England Journal of Medicine</i> , 2010, 362, 2370-2379.	27.0	1,075
137	Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension. <i>Journal of Hepatology</i> , 2010, 53, 558-567.	3.7	178
138	Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2009, 136, 1651-1658.	1.3	372
139	The clinical use of HVPG measurements in chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 573-582.	17.8	576
140	The management of portal hypertension: Rational basis, available treatments and future options. <i>Journal of Hepatology</i> , 2008, 48, S68-S92.	3.7	248
141	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. <i>Journal of Hepatology</i> , 2008, 48, 229-236.	3.7	284
142	Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1412-1417.	4.4	175
143	Portal Hypertension and Gastrointestinal Bleeding. <i>Seminars in Liver Disease</i> , 2008, 28, 003-025.	3.6	114
144	The Treatment of Acute Variceal Bleeding. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S312-S317.	2.2	52

#	ARTICLE	IF	CITATIONS
145	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. <i>Journal of Hepatology</i> , 2007, 46, 1040-1046.	3.7	203
146	Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. <i>Journal of Hepatology</i> , 2006, 44, 1040-1045.	3.7	6
147	Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 506-512.	0.4	228
148	Animal models of portal hypertension. <i>World Journal of Gastroenterology</i> , 2006, 12, 6577.	3.3	110
149	Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2006, 43, 485-491.	7.3	106
150	Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2006, 26, 348-362.	3.6	182
151	Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G980-G987.	3.4	176
152	Portal Hypertension. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S125-S130.	2.2	115
153	Variceal Bleeding: Pharmacological Therapy. <i>Digestive Diseases</i> , 2005, 23, 18-29.	1.9	21
154	The Management of Portal Hypertension. <i>Clinics in Liver Disease</i> , 2005, 9, 685-713.	2.1	29
155	Medical Management of Variceal Bleeding in Patients with Cirrhosis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004, 18, 109-113.	1.7	11
156	Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study. <i>Gastroenterology</i> , 2004, 126, 469-475.	1.3	468
157	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. <i>Gastroenterology</i> , 2004, 126, 749-755.	1.3	258
158	Management of gastrointestinal bleeding in patients with cirrhosis of the liver. <i>Seminars in Hematology</i> , 2004, 41, 8-12.	3.4	22
159	Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. <i>Hepatology</i> , 2003, 37, 172-181.	7.3	126
160	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. <i>Hepatology</i> , 2003, 37, 378-384.	7.3	78
161	Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. <i>Hepatology</i> , 2003, 37, 902-908.	7.3	456
162	Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. <i>Hepatology</i> , 2003, 38, 1378-1383.	7.3	17

#	ARTICLE	IF	CITATIONS
163	Current management of portal hypertension. Journal of Hepatology, 2003, 38, 54-68.	3.7	245
164	Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. Journal of Hepatology, 2003, 39, 515-521.	3.7	68
165	The HVPG-response to pharmacological treatment of portal hypertension predicts prognosis and the risk of developing complications of cirrhosis. Journal of Hepatology, 2002, 36, 15.	3.7	8
166	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	121
167	Novel approaches to treat portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S232-S241.	2.8	3
168	Nitric oxide and portal hypertension. Metabolic Brain Disease, 2002, 17, 311-324.	2.9	29
169	Somatostatin and analogues in portal hypertension. Hepatology, 2002, 35, 1305-1312.	7.3	87
170	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	113